Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+advanced systemic mastocytosis

被引：183

作者：

Jawhar, M. ^{[1
]}

Schwaab, J. ^{[1
]}

Schnittger, S. ^{[2
]}

Meggendorfer, M. ^{[2
]}

Pfirrmann, M. ^{[3
]}

Sotlar, K. ^{[4
]}

Horny, H-P ^{[4
]}

Metzgeroth, G. ^{[1
]}

Kluger, S. ^{[1
]}

Naumann, N. ^{[1
]}

Haferlach, C. ^{[2
]}

Haferlach, T. ^{[2
]}

Valent, P. ^{[5
]}

Hofmann, W-K ^{[1
]}

Fabarius, A. ^{[1
]}

Cross, N. C. P. ^{[6
,7
]}

Reiter, A. ^{[1
]}

机构：

[1] Univ Med Ctr Mannheim, Dept Hematol & Oncol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany

[2] MLL Munich Leukemia Lab, Munich, Germany

[3] Univ Munich, Inst Med Informat Biometry & Epidemiol, Munich, Germany

[4] Univ Munich, Inst Pathol, Thalkirchner Str 36, D-80539 Munich, Germany

[5] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Ludwig Boltzmann Cluster Oncol, Vienna, Austria

[6] Wessex Reg Genet Lab, Salisbury, Wilts, England

[7] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England

来源：

LEUKEMIA | 2016年 / 30卷 / 01期

基金：

奥地利科学基金会;

关键词：

CHRONIC MYELOMONOCYTIC LEUKEMIA; PRIMARY MYELOFIBROSIS; DIAGNOSIS; D816V; STRATIFICATION; CLASSIFICATION; PROGNOSIS; KITD816V; UPDATE; CELLS;

D O I：

10.1038/leu.2015.284

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Most patients with KIT D816V(+) advanced systemic mastocytosis (SM) are characterized by somatic mutations in additional genes. We sought to clarify the prognostic impact of such mutations. Genotype and clinical characteristics of 70 multi-mutated KIT D816V(+) advanced SM patients were included in univariate and multivariate analyses. The most frequently identified mutated genes were TET2 (n=33 of 70 patients), SRSF2 (n=30), ASXL1 (n=20), RUNX1 (n=16) and JAK2 (n=11). In univariate analysis, overall survival (OS) was adversely influenced by mutations in SRSF2 (P<0.0001), ASXL1 (P=0.002) and RUNX1 (P=0.03), but was not influenced by mutations in TET2 or JAK2. In multivariate analysis, SRSF2 and ASXL1 remained the most predictive adverse indicators concerning OS. Furthermore, we found that inferior OS and adverse clinical characteristics were significantly influenced by the number of mutated genes in the SRSF2/ASXL1/RUNX1 (S/A/R) panel (P<0.0001). In conclusion, the presence and number of mutated genes within the S/A/R panel are adversely associated with advanced disease and poor survival in KIT D816V(+) SM. On the basis of these findings, inclusion of molecular markers should be considered in upcoming prognostic scoring systems for patients with SM.

引用

页码：136 / 143

页数：8

共 35 条

[1] ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases [J].

Damaj, Gandhi ;

Joris, Magalie ;

Chandesris, Olivia ;

Hanssens, Katia ;

Soucie, Erinn ;

Canioni, Danielle ;

Kolb, Brigitte ;

Durieu, Isabelle ;

Gyan, Emanuel ;

Livideanu, Cristina ;

Cheze, Stephane ;

Diouf, Momar ;

Garidi, Reda ;

Georgin-Lavialle, Sophie ;

Asnafi, Vahid ;

Lhermitte, Ludovic ;

Lavigne, Christian ;

Launay, David ;

Arock, Michel ;

Lortholary, Olivier ;

Dubreuil, Patrice ;

Hermine, Olivier .

PLOS ONE, 2014, 9 (01)

[2] The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis [J].

Erben, Philipp ;

Schwaab, Juliana ;

Metzgeroth, Georgia ;

Horny, Hans-Peter ;

Jawhar, Mohamad ;

Sotlar, Karl ;

Fabarius, Alice ;

Teichmann, Martina ;

Schneider, Sven ;

Ernst, Thomas ;

Mueller, Martin C. ;

Giehl, Michelle ;

Marx, Alexander ;

Hartmann, Karin ;

Hochhaus, Andreas ;

Hofmann, Wolf-Karsten ;

Cross, Nicholas C. P. ;

Reiter, Andreas .

ANNALS OF HEMATOLOGY, 2014, 93 (01) :81-88

[3] RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group [J].

Gaidzik, Verena I. ;

Bullinger, Lars ;

Schlenk, Richard F. ;

Zimmermann, Andreas S. ;

Roeck, Juergen ;

Paschka, Peter ;

Corbacioglu, Andrea ;

Krauter, Juergen ;

Schlegelberger, Brigitte ;

Ganser, Arnold ;

Spaeth, Daniela ;

Kuendgen, Andrea ;

Schmidt-Wolf, Ingo G. H. ;

Goetze, Katharina ;

Nachbaur, David ;

Pfreundschuh, Michael ;

Horst, Heinz A. ;

Doehner, Hartmut ;

Doehner, Konstanze .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (10) :1364-1372

[4] Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial [J].

Gotlib, Jason ;

Kluin-Nelemans, Hanneke C. ;

George, Tracy I. ;

Akin, Cem ;

Sotlar, Karl ;

Hermine, Olivier ;

Awan, Farrukh ;

Hexner, Elizabeth O. ;

Mauro, Michael ;

Sternberg, David ;

Villeneuve, Matthieu ;

Emery-Salbert, Fabienne ;

Stanek, Eric ;

Hartmann, Karin ;

Horny, Hans-Peter ;

Valent, Peter ;

Reiter, Andreas .

BLOOD, 2014, 124 (21)

[5] The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients [J].

Guglielmelli, P. ;

Lasho, T. L. ;

Rotunno, G. ;

Score, J. ;

Mannarelli, C. ;

Pancrazzi, A. ;

Biamonte, F. ;

Pardanani, A. ;

Zoi, K. ;

Reiter, A. ;

Duncombe, A. ;

Fanelli, T. ;

Pietra, D. ;

Rumi, E. ;

Finke, C. ;

Gangat, N. ;

Ketterling, R. P. ;

Knudson, R. A. ;

Hanson, C. A. ;

Bosi, A. ;

Pereira, A. ;

Manfredini, R. ;

Cervantes, F. ;

Barosi, G. ;

Cazzola, M. ;

Cross, N. C. P. ;

Vannucchi, A. M. ;

Tefferi, A. .

LEUKEMIA, 2014, 28 (09) :1804-1810

[6] Landscape of genetic lesions in 944 patients with myelodysplastic syndromes [J].

Haferlach, T. ;

Nagata, Y. ;

Grossmann, V. ;

Okuno, Y. ;

Bacher, U. ;

Nagae, G. ;

Schnittger, S. ;

Sanada, M. ;

Kon, A. ;

Alpermann, T. ;

Yoshida, K. ;

Roller, A. ;

Nadarajah, N. ;

Shiraishi, Y. ;

Shiozawa, Y. ;

Chiba, K. ;

Tanaka, H. ;

Koeffler, H. P. ;

Klein, H-U ;

Dugas, M. ;

Aburatani, H. ;

Kohlmann, A. ;

Miyano, S. ;

Haferlach, C. ;

Kern, W. ;

Ogawa, S. .

LEUKEMIA, 2014, 28 (02) :241-247

[7] SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes [J].

Hanssens, Katia ;

Brenet, Fabienne ;

Agopian, Julie ;

Georgin-Lavialle, Sophie ;

Damaj, Gandhi ;

Cabaret, Laure ;

Chandesris, Maria Olivia ;

de Sepulveda, Paulo ;

Hermine, Olivier ;

Dubreuil, Patrice ;

Soucie, Erinn .

HAEMATOLOGICA, 2014, 99 (05) :830-835

[8]

Horny H-P., 2008, WHO classification of Tumours of Haematopoietic and Lymphoid Tissues, V4th, P54

[9] Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia [J].

Itzykson, Raphael ;

Kosmider, Olivier ;

Renneville, Aline ;

Gelsi-Boyer, Veronique ;

Meggendorfer, Manja ;

Morabito, Margot ;

Berthon, Celine ;

Ades, Lionel ;

Fenaux, Pierre ;

Beyne-Rauzy, Odile ;

Vey, Norbert ;

Braun, Thorsten ;

Haferlach, Torsten ;

Dreyfus, Francois ;

Cross, Nicholas C. P. ;

Preudhomme, Claude ;

Bernard, Olivier A. ;

Fontenay, Michaela ;

Vainchenker, William ;

Schnittger, Susanne ;

Birnbaum, Daniel ;

Droin, Nathalie ;

Solary, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (19) :2428-+

[10] Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event [J].

Jawhar, M. ;

Schwaab, J. ;

Schnittger, S. ;

Sotlar, K. ;

Horny, H-P ;

Metzgeroth, G. ;

Mueller, N. ;

Schneider, S. ;

Naumann, N. ;

Walz, C. ;

Haferlach, T. ;

Valent, P. ;

Hofmann, W-K ;

Cross, N. C. P. ;

Fabarius, A. ;

Reiter, A. .

LEUKEMIA, 2015, 29 (05) :1115-1122

← 1 2 3 4 →